RxDoctor Payments Data

Graham Meeks

Nurse Practitioner · Mount Vernon, WANPI 1043729619

Payments from drug & device makers

$1,418in general payments, 2019–2025

Across 48 payments — averaging $29.55 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novartis$239
  • Impulse Dynamics (USA) Inc.$201
  • Actelion Pharmaceuticals US, Inc.$186
  • Janssen Scientific Affairs, LLC$179
  • AstraZeneca$147
  • Johnson & Johnson$118
  • plus $348 from 7 others

What the payments were for

  • Food & beverage$1,25488%
  • Education$16512%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,418 in reported general payments places this provider in the 90th percentile of 2,466 nurse practitioner providers in Washington.

See all nurse practitioner providers in Washington

Medicare billing

Part B allowed, 2024
$51,748
Medicare patients
349
Services billed
826

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban247$284,426
JardianceEmpagliflozin232$284,010
EntrestoSacubitril/Valsartan170$228,718
XareltoRivaroxaban61$70,899
FarxigaDapagliflozin Propanediol27$25,196
Repatha SureclickEvolocumab19$17,914
CorlanorIvabradine Hcl17$12,575
BrilintaTicagrelor17$12,289
Metoprolol Succinate381$8,532
Torsemide190$5,536
Dabigatran EtexilateDabigatran Etexilate Mesylate16$2,880
Carvedilol222$2,822
Potassium Chloride109$2,648
Digoxin73$1,806
Spironolactone208$1,670

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
NovartisEntresto$239$228,718170 claims
Johnson & JohnsonXarelto$118$70,89961 claims
AstraZenecaFarxiga, Brilinta$147$37,48544 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 2,466 nurse practitioner providers in Washington.

Other nurse practitioner in Mount Vernon

See the full list for Washington

Where these figures come from

Is this you, or does something look wrong? →